Special reportResolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement☆,☆☆
References (123)
- et al.
Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application
Am Heart J
(1982) - et al.
Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men
Lancet
(1986) Epidemiology of coronary heart disease: the Framingham Study
Am J Med
(1984)- et al.
Antihypertensive treatment and plasma lipoprotein levels: the associations in data from a population study
Am J Med
(1986) - et al.
Elevation of serum lipid levels during diuretic therapy of hypertension
Am J Med
(1976) - et al.
The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials
Prog Cardiovasc Dis
(1986) - et al.
Renal parenchymal involvement in essential hypertension
Med Clin North Am
(1987) - et al.
Hypertension and renal diseases
Am J Kidney Dis
(1987) - et al.
The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation
Atherosclerosis
(1985) Cardiac hypertrophy: useful adaptation or pathologic process?
Am J Med
(1980)
Cardiac renin-angiotensin system molecular and functional aspects
Am J Med
Usefulness of echocardiographic left ventricular hypertrophy in predicting new coronary events and atherothrombotic brain infarction in patients over 62 years of age
Am J Cardiol
Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa
Am J Cardiol
Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive humans
Am J Med
Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension
Am J Cardiol
Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator
J Am Coll Cardiol
Nifedipine administered post-reperfusion ablates systolic contractile dysfunction of postischemic “stunned” myocardium
J Am Coll Cardiol
Functional infarct expansion, left ventricular dilation and iso-volumic relaxation time following coronary occlusion: a two-dimensional echocardiographic study
J Am Coll Cardiol
Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart
Eur J Pharmacol
Neuroendocrine changes in acute myocardial infarction
Am J Med
Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction
Am Heart J
Myocardial infarct expansion, infarct extension and reinfarction: pathophysiologic concepts
Prog Cardiovasc Dis
Lowering plasma cholesterol levels decreases risk of coronary heart disease: an overview of clinical trials
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
JAMA
The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
JAMA
Niacin or lovastatin, combined with colestipol, regress coronary atherosclerosis and prevent clinical events in men with elevated apolipoprotein B [Abstract]
Circulation
Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study
Circulation
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
JAMA
Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults
Arch Intern Med
Relative impact of targeted versus population-wide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model
Circulation
Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction
The place of HDL in clinical management. A perspective from the National Cholesterol Education Program
Arch Intern Med
Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity
N Engl J Med
5α-Cholest-8(14)-en-3β-ol-15-one lowers serum cholesterol and induces profound changes in the levels of lipoprotein cholesterol and apoproteins in monkeys fed a diet of moderate cholesterol content
Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit
Diet, serum cholesterol and death from coronary heart disease: the Western Electric Study
N Engl J Med
Treatment of hypertension and its effect on cardiovascular risk factors: data from the Framingham Heart Study
Circulation
A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension
N Engl J Med
Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg
JAMA
Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the multiple Risk Factor Intervention Trial
Am J Cardiol
The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline. The HDFP experience
Circulation
1984 Report
Arch Intern Med
The incidence of treated and stage renal disease in the eastern United States
Am J Public Health
Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus
N Engl J Med
Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes
N Engl J Med
Therapeutic implications of converting-enzyme inhibitors in renal disease
Am J Kidney Dis
Platelet-derived growth factor synthesis in mesangial cells: induction by multiple peptide mitogens
N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation
J Clin Invest
Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial cell proliferation
Am J Pathol
Disparities in incidence of diabetic end stage renal disease according to race and type of diabetes
N Engl J Med
Cited by (0)
- ☆
This article is based on the consensus reached by participants at a workshop entitled, “Frontiers of cardiovascular therapy and cardiac protection: Resolved and unresolved issues,” held January 8–10, 1989 and subsequently updated. Cochairmen: Eugene Braunwald, MD, and Victor Dzau, MD, Boston, Mass. Participants: Lewis C. Becker, MD, Baltimore, Md.; Roland C. Blantz, MD, San Diego, Calif.; B. Greg Brown, MD, PhD, Seattle, Wash.; Kanu Chatterjee, MB, FRCP, San Francisco, Calif.; Aram V. Chobanian, MD, Boston, Mass.; A. Richard Christlieb, MD, Boston, Mass.; Robert J. Cody, MD, Columbus, Ohio; Jay N. Cohn, MD, Minneapolis, Minn.; John E. Deanfield, MD, MRCP, London, England; Curt D. Furberg, MD, PhD, Winston-Salem, N.C.; Valentin Fuster, MD, New York, N.Y.; Lee Goldman, MD, Boston, Mass.; Sidney Goldstein, MD, Detroit, Mich.; DeWitt Goodman, MD, New York, N.Y.; Sidney O. Gottlieb, MD, Baltimore, Md.; Charles H. Hennekens, MD, Boston, Mass.; Donald Hunninghake, MD, Minneapolis, Minn.; William B. Kannel, MD, MPH, Boston, Mass.; J. Ward Kennedy, MD, Seattle, Wash.; Robert A. Kloner, MD, PhD, Los Angeles, Calif.; Beverly H. Lorell, MD, Boston, Mass.; Joe M. McCord, PhD, Mobile, Ala.; Joel Morganroth, MD, Philadelphia, Pa.; Bertram Pitt, MD, Detroit, Mich.; Leopoldo Raij, MD, Minneapolis, Minn.; Robert Roberts, MD, Houston, Texas; Jean-Lucien Rouleau, MD, FRCP, Montreal, Canada; Edmund H. Sonnenblick, MD, Bronx, N.Y.; Herman A. Tyroler, MD, Chapel Hill, N.C.; Paul M. Vanhoutte, MD, PhD, Houston, Texas; Michael A. Weber, MD, Long Beach, Calif.; Harry Wesseling, MD, PhD, Groningen, The Netherlands; Harvey D. White, MB, ChB, FRACP, Auckland, New Zealand; James T. Willerson, MD, Houston, Texas; and David O. Williams, MD, Providence, R.I.
- ☆☆
The workshop on which this article is based was supported by an educational grant from Bristol-Myers-Squibb Corporation, Princeton, N. J.